^
    2ms
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Mar 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    JNJ-6420
    6ms
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=111, Recruiting, Janssen Research & Development, LLC | N=76 --> 111 | Trial completion date: Jul 2025 --> Oct 2025
    Enrollment change • Trial completion date • Metastases
    |
    JNJ-6420
    7ms
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=76, Recruiting, Janssen Research & Development, LLC | N=134 --> 76
    Enrollment change • Metastases
    |
    JNJ-6420
    12ms
    A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=100, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Mar 2023 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    JNJ-6420
    almost2years
    Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (ASCO 2022)
    Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of 10 Feb 2022, 4 sites have been initiated and 23 patients enrolled; currently, dose escalation is ongoing.
    P1 data • IO biomarker
    |
    AR (Androgen receptor) • KLK2 (Kallikrein-related peptidase 2)
    |
    JNJ-6420
    over2years
    Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. (ASCO-GU 2022)
    Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of Sep 2021, 4 sites have been initiated and 14 pts enrolled; currently, dose escalation is ongoing.
    P1 data • IO biomarker
    |
    AR (Androgen receptor) • KLK2 (Kallikrein-related peptidase 2)
    |
    JNJ-6420